Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Risk & Volatility

MindWalk has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Valuation & Earnings

This table compares MindWalk and Calliditas Therapeutics AB (publ)”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59 million	2.89	-$21.69 million	($0.60)	-1.83
Calliditas Therapeutics AB (publ)	$1.60 billion	0.74	-$43.96 million	($1.85)	-21.62

MindWalk has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

6.7% of MindWalk shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for MindWalk and Calliditas Therapeutics AB (publ), as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	0	0	1.50
Calliditas Therapeutics AB (publ)	0	0	0	0	0.00

Profitability

This table compares MindWalk and Calliditas Therapeutics AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-145.58%	-56.75%	-31.55%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Summary

MindWalk beats Calliditas Therapeutics AB (publ) on 8 of the 12 factors compared between the two stocks.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.